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Several  cell  types,  including  BM  cells  (BMCs),  ES  cells, 



















































mMAPC-U and hMAPC-U engraftment and differentiation. (A–F) At 14 days, cell patches (dotted lines in A and B) were found by in vivo (A) or 
ex vivo (B) imaging, GFP fluorescence (C), and anti-GFP staining in cross sections (D). Note positioning of the patches near α-SMA+ (red in 
E) vessels and the surrounding CD45+ (red in F) clusters. (G–I) At 14 days, confocal imaging revealed some GFP+ cells coexpressing CD31 or 
α-SMA (arrowheads in G and H, respectively). A limited number of regenerating SkMBs were GFP+ (thus donor derived; revealed by anti-GFP 
staining; I). (J–L) At 5 weeks, mMAPC-U persisted (shown by in vivo imaging, J; and anti-GFP staining, K and L). Note that donor-derived 
regenerating fibers (GFP+ cells in K) were still apparent and that cell number was less than it was at 14 days (compare D and L). (M–P) At 30 
days, hMAPC-U stably engrafted (revealed by large human vimentin+ [green] cell patches intercalated between muscle fibers [M and N] and as 
scattered cells around vessels [P]). Cells were detected in the endothelial layer of vessels by a human-specific anti-CD31 antibody (green in 
O), indicating EC differentiation, and in some cells the human vimentin signal (green) colocalized (yellow; white arrowheads) with α-SMA (red), 
indicating their SMC identity in P. Images in A, C, D, E, G–J, L, M, O, and P are from adductor; images in B, F, I, and K from gastrocnemius and 
N from quadriceps muscle. DAPI was used as nuclear counterstain in C and E and M–O and Topro (Molecular Probes) in H and P. Scale bars: 
50 μm (G–I, K), 100 μm (C, D, F, L, M, O, and P), 200 μm (E and N), and 500 μm (A, B, and J).
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mMAPC-VP and mBMC engraftment and differentiation. (A–C) At 14 days, 
mMAPC-VP were lower in number compared with mMAPC-U (compare A and 
Figure 1C). Confocal imaging revealing more GFP+ cells coexpressing CD31 
(B) and α-SMA (arrowheads in C). Overexposure in the DAPI channel was 
used to reveal muscle tissue in A. (D–G) At 14 days, anti-GFP staining revealed 
that mBMCs engrafted mostly in connective and fat tissue outside muscle (D) 
and only occasionally intercalated between muscle cells (E). Confocal analysis 
showing that mBMCs (green; F) did not integrate in but were located outside 
(arrowheads in F) vessels (CD31; red; F) and that most of the cells (green; 
G) colocalized (yellow; G) with the pan-hematopoietic marker CD45 (red; G). 
Images in A–D, F, and G are from adductor; the image in E is from gastrocne-
mius muscle. Topro was used as nuclear counterstain in F. Scale bars: 40 μm 
(B and C), 62.5 μm (F and G), 100 μm (D and E), and 150 μm (A).
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Late effects of mMAPC-U, mMAPC-VP, 

























Early effects of mMAPC-U, mMAPC-VP, and mBMCs 
in moderate ischemia. (A–D) α-SMA (red) staining at 
9 days in adductor of vehicle- (A), mMAPC-U– (B), 
mBMC– (C), or mMAPC-VP–treated mice (D). Overex-
posure in the DAPI channel was used to reveal muscle 
tissue. (E) Left: Laser Doppler measurements in left legs 
(expressed as % versus the nonligated right leg) before 
(–) and after (+) ligation of vehicle- (red), mMAPC-U– 
(black), mBMC- (gray), or mMAPC-VP–treated mice 
(blue). Right: Swim endurance test measuring hind limb 
function (expressed as % of baseline [day -1] perfor-
mance) in vehicle- (red), mMAPC-U– (black), mBMC- 
(gray), or mMAPC-VP–injected mice (blue). The dotted 
line indicates the performance level of mice in which 
only one femoral artery was ligated 9 days prior and 
that were untreated. (F–H) Magnetic resonance spec-
tra (MRS) recorded at 9 days to determine the ener-
getic status (expressed as Σ[PCr/Pi, PCr/γ-ATP], with 
23 as normal reference value) in the lower limb muscle 
showing representative overlays of the spectrum of a 
nonischemic mouse (gray in F–H) and those of vehicle- 
(red; F), mMAPC-U– (blue; G), and mBMC- or mMAPC-
VP-injected mice (green; H). *P < 0.05 versus vehicle for 
each corresponding time point. Scale bars: 100 μm.
Table 
Early and late effects of mMAPC-U, mMAPC-VP, and mBMCs on limb perfusion, status, and 
function in moderate limb ischemia
	 	 Vehicle	 mMAPC-U	 mBMCs	 mMAPC-VP
Early	phase	(day	9)
Vascular bed (adductor)
 Collaterals (% α-SMA+ area); n = 9 0.9 ± 0.1 2.7 ± 0.3A,B 1.6 ± 0.3A 1.3 ± 0.2C
 Capillaries (no./mm2); n = 9 580 ± 48 807 ± 46A 734 ± 65A 868 ± 93A
Blood flow (%);D n = 6–8	 39 ± 2	 63 ± 9A,B	 48 ± 5A	 47 ± 2A
Swim endurance (%);E n = 14–7	 23 ± 6	 58 ± 12A	 49 ± 8A	 45 ± 8A
MRSI (AU);F n = 4–6	 12 ± 2	 18 ± 2A	 16 ± 3	 16 ± 2
Late	phase	(days	21–35)
Blood flow (%);D day 21; n = 5–6	 52 ± 3	 83 ± 1A,B	 47 ± 7	 50 ± 1
Swim endurance (%);E day 21; n = 6 45 ± 6	 85 ± 13B,C	 14 ± 4A	 44 ± 9
Tissue viability (%);G day 28; n = 5	 38 ± 2 74 ± 5A,B 23 ± 6A 43 ± 4
Fibrosis (%);H day 28; n = 5 11 ± 1	 6 ± 1A,B	 14 ± 2A	 10 ± 1
Toe necrosis (%);I day 35; n = 15–17 33	 0	 69	 30
Data represent the mean ± SEM). AP < 0.05 versus vehicle; BP < 0.05 versus mBMC and mMAPC-VP; 
CP = 0.06 versus vehicle. D% of nonligated leg; E% of baseline endurance; Fsum of PCr/Pi (phospho-
creatine/inorganic phosphate) and PCr/γ-ATP ratios; G% TTC+ area of total muscle area; H% Sirius red+ 
area of total muscle area; Iincidence. MRSI, magnetic resonance spectroscopy/imaging; TTC, tetraphen-
yltetrazolium chloride.
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Trophic effects of mMAPC-U on vascu-
lar and muscle cells. We hypothesized 





















Effects of mMAPC-U and hMAPC-U in severe limb ischemia. Finally, we 
tested the potential of mMAPC-U, mMAPC-U2 (2 independently 
Figure 
Late effects of mMAPC-U, mMAPC-VP, and mBMCs in moderate ischemia. (A) Laser Doppler mea-
surements in left legs (expressed as % of the nonligated right leg) of vehicle- (red), mMAPC-U– 
(black), mBMC- (gray), or mMAPC-VP–treated mice (blue). (B) Swim performance (expressed as % 
versus day –1 [baseline]) of vehicle- (red), mMAPC-U– (black), mBMC- (gray), or mMAPC-VP–treated 
mice (blue). (C) Table summarizing clinical evaluation of all treatment regimens up to 5 weeks after 
transplantation. Representative images (D–G) and corresponding quantification (H) of whole-tissue 
(gastrocnemius muscle, cut into 2 slices of equal thickness) viability (red, viable tissue) by triphenyltet-
razolium chloride (TTC) staining 4 weeks after transplantation in vehicle (D; red in H), mMAPC-U (E; 
black in H), mBMC (F; gray in H), and mMAPC-VP (G; blue in H) groups. (I–L) Sirius red–stained cross 
sections of gastrocnemius muscle 5 weeks after transplantation of vehicle- (I), mMAPC-U– (J), mBMC- 
(K), or mMAPC-VP–injected (L) animals. All analyses were performed on 6–12 mice per group. The 
insets in E and J show a nonischemic muscle. *P < 0.05 versus vehicle for each corresponding time 
point. Scale bars: 500 μm (I–L). Original magnification, ×2 (D–G); ×0.66 (inset E); ×2.5 (inset J).
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Differential effects of mMAPC-U, 
mMAPC-VP, and mBMCs in moder-
ate ischemia. (A) Analysis of necrosis 
(defined as the presence of fat cells 
[black arrowhead], inflammatory infiltrates 
[white arrowhead], and “ghost” muscle 
cells devoid of a nucleus [asterisk]; 
expressed as % versus total muscle area) 
on H&E-stained cross sections in vehi-
cle, mMAPC-U, mBMC, or mMAPC-VP 
groups. (B–F) Analysis of fibrosis on 
Sirius red–stained cross sections in 
vehicle (B), mMAPC-U (C), mBMC 
(D), or mMAPC-VP (E) groups. (G–K) 
Analysis of inflammation (CD45+ area 
in red, expressed as % versus total 
muscle area in K) on cross sections in 
vehicle (G), mMAPC-U (H), mBMC (I), 
or mMAPC-VP (J) groups. (L) Analysis 
of muscle regeneration (fibers with cen-
tral nuclei, expressed as % versus total 
muscle area) on H&E-stained cross sec-
tions in vehicle, mMAPC-U, mBMC, or 
mMAPC-VP groups. (M–Q) Analysis of 
myogenesis (desmin+ area, expressed 
as % versus total muscle area in Q) on 
cross sections in vehicle (M), mMAPC-U 
(N), mBMC (O), or mMAPC-VP (P) 
groups. (R–V) Analysis of satellite cells 
(N-CAM+ area, expressed as % versus 
total muscle area in V) on cross sections 
in vehicle (R), mMAPC-U (S), mBMC (T), 
or mMAPC-VP (U) groups. Red bars in 
A, F, K, L, Q, and V correspond to vehi-
cle, black bars to mMAPC-U, gray bars 
to mBMC, and blue bars to mMAPC-VP 
groups. All images are from the gastroc-
nemius muscle. Hematoxylin was used 
as nuclear counterstain in A, L, M–P, 
and R–U and DAPI in G–J. *P < 0.05 
versus vehicle. Scale bars: 62.5 μm (A, 
L, and R–U), 130 μm (B–E), and 1 mm 
(G–J, M–P).
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Effects of mMAPC-U and hMAPC-U in severe limb ischemia
	 	 Vehicle	 mMAPC-U	 mMAPC-U2	 hMAPC-U
Collaterals (% α-SMA+ area); day 21; n = 6	 0.5 ± 0.1	 1.5 ± 0.2G	 1.2 ± 0.1G	 1.4 ± 0.2G
Perfusional recovery (%);A n = 8–12
 Day 9 8 ± 3 17 ± 3G 21 ± 4G 14 ± 3G
 Day 14 9 ± 3 23 ± 3G 25 ± 5G 23 ± 4G
 Day 21 12 ± 3 23 ± 3G 29 ± 3G 25 ± 4G
Treadmill endurance (%);B n = 7–9
 Day 9 163 ± 16 176 ± 11 151 ± 12 184 ± 20
 Day 14 213 ± 17 270 ± 24H 243 ± 22 293 ± 20G
 Day 21 214 ± 18 345 ± 43G 273 ± 19I 336 ± 21G
Tissue viability (%);C day 21; n = 5–6	 31 ± 8 59 ± 5G 56 ± 7G 64 ± 4G
Fibrosis (%);D day 21; n = 5–6 29 ± 2	 17 ± 4G	 14 ± 3G	 16 ± 3G
Myogenesis (%);E day 21; n = 5–6	 12 ± 1 31 ± 5G 18 ± 3H 24 ± 4G
Toe necrosis (%);F day 21; n = 7–13 91	 29	 31	 33
Data represent mean ± SEM. A% increase versus day 5 relative to nonligated leg; B% of day 5 endurance; 
C% TTC+ area of total muscle area; D% Sirius red+ area of total muscle area; E% desmin+ area of total 
muscle area; Fincidence. GP < 0.05 versus vehicle; HP = 0.07 versus vehicle; IP = 0.05 versus vehicle.
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Effects of mMAPC-U and hMAPC-U in severe isch-
emia. (A–D) α-SMA (red) staining at 21 days in adduc-
tor of vehicle- (A), mMAPC-U– (B), mMAPC-U2– (C), or 
hMAPC-U–treated mice (D). Overexposure in the DAPI 
channel was used to reveal muscle tissue. (E and F) 
Laser Doppler measurements (E) in left legs (expressed 
as % improvement versus pretransplant [day +5] and 
relative to the nonligated right leg); and treadmill endur-
ance test (F) measuring hind limb function (expressed 
as % of pretransplant performance [day +5]) at several 
time points after (+) ligation of vehicle- (red), mMAPC-U– 
(black), mMAPC-U2– (gray), or hMAPC-U–treated 
mice (blue). (G–J) Sirius red–stained cross sections 
of gastrocnemius muscle 3 weeks after transplanta-
tion of vehicle- (G), mMAPC-U– (H), mMAPC-U2– (I), 
or hMAPC-U–injected (J) animals. (K) Quantitative 
analysis of α-SMA (in adductor), viability (TTC), fibrosis 
(Sirius red), and myogenesis (desmin) staining (all in 
gastrocnemius), expressed as percent positive staining 
per muscle area in vehicle- (red), mMAPC-U– (black), 
mMAPC-U2– (gray), or hMAPC-U–treated mice (blue). 
All analyses were performed on 6–12 mice per group. 
*P < 0.05 versus vehicle for each corresponding time 
point; †P = 0.05 versus vehicle; #P = 0.07 versus vehi-
cle. Scale bars: 250 μm (A–D) and 62.5 μm (G–J).
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through  paracrine  mechanisms.  Circulation. 
109:1543–1549.
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therapy in ischemic limb disease through growth 
factor  secretion  by  cultured  adipose  tissue-
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